Peramivir
Total Payments
$154,514
Transactions
41
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $154,514 | 41 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $149,564 | 39 | 96.8% |
| Consulting Fee | $4,950 | 2 | 3.2% |
Payments by Type
Research
$149,564
39 transactions
General
$4,950
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, randomized, open label, active-controlled study to evaluate the safety, pharmacokinetics and effectiveness of IV peramivir compared to oral oseltamivir in pediatric subjects with acute uncomplicated influenza | BioCryst Pharmaceuticals, Inc. | $149,564 | 0 |
Top Doctors Receiving Payments for Peramivir
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cincinnati, OH | $149,564 | 39 |
| , MD | Infectious Disease | Charleston, SC | $4,950 | 2 |
Ad
Manufacturing Companies
- BioCryst Pharmaceuticals, Inc. $154,514
Product Information
- Type Drug
- Total Payments $154,514
- Total Doctors 1
- Transactions 41
About Peramivir
Peramivir is a drug associated with $154,514 in payments to 1 healthcare providers, recorded across 41 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $154,514 was paid across 41 transactions to 1 doctors.
The most common payment nature for Peramivir is "Unspecified" ($149,564, 96.8% of total).
Peramivir is associated with 1 research study, including "A Phase 3, randomized, open label, active-controlled study to evaluate the safety, pharmacokinetics and effectiveness of IV peramivir compared to oral oseltamivir in pediatric subjects with acute uncomplicated influenza" ($149,564).